BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Langhans B, Nischalke HD, Krämer B, Hausen A, Dold L, van Heteren P, Hüneburg R, Nattermann J, Strassburg CP, Spengler U. Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol 2017;66:888-96. [PMID: 28040549 DOI: 10.1016/j.jhep.2016.12.019] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Hirano J, Yoshio S, Sakai Y, Songling L, Suzuki T, Itoh Y, Zhang H, Chen DV, Haga S, Oomori H, Kodama T, Maeda Y, Ono Y, Takahashi Y, Standley DM, Yamamoto M, Moriishi K, Moriya K, Kanto T, Takehara T, Koike K, Matsuura Y, Okamoto T. Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. Proc Natl Acad Sci U S A 2021;118:e2026184118. [PMID: 34035171 DOI: 10.1073/pnas.2026184118] [Reference Citation Analysis]
2 Gorin JB, Malone DFG, Strunz B, Carlsson T, Aleman S, Björkström NK, Falconer K, Sandberg JK. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Sci Rep 2020;10:2081. [PMID: 32034167 DOI: 10.1038/s41598-020-58768-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Braz AMM, Winckler FC, Binelli LS, Chimeno LG, Lopes LBM, Lima RS, Simões RP, Grotto RMT, Golim MA, Silva GF. Inflammation response and liver stiffness: predictive model of regression of hepatic stiffness after sustained virological response in cirrhotics patients with chronic hepatitis C. Clin Exp Med 2021. [PMID: 33835323 DOI: 10.1007/s10238-021-00708-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
6 van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, Sinnige MJ, van Nuenen AC, de Vree JML, Klenerman P, Barnes E, Kootstra NA, Reesink HW. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Res 2017;146:139-45. [PMID: 28844749 DOI: 10.1016/j.antiviral.2017.08.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
7 Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J Hepatol 2018; 10(12): 898-906 [PMID: 30631394 DOI: 10.4254/wjh.v10.i12.898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
9 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
10 Stevenson TJ, Barbour Y, McMahon BJ, Townshend-Bulson L, Hewitt AM, Espera HGF, Homan C, Holck P, Luna SV, Knall C, Simons BC. Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection. Open Forum Infect Dis 2019;6:ofz223. [PMID: 31249845 DOI: 10.1093/ofid/ofz223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol 2021;12:726419. [PMID: 34456931 DOI: 10.3389/fimmu.2021.726419] [Reference Citation Analysis]
12 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Reference Citation Analysis]
13 Chu PS, Nakamoto N, Taniki N, Ojiro K, Amiya T, Makita Y, Murata H, Yamaguchi A, Shiba S, Miyake R, Katayama T, Ugamura A, Ikura A, Takeda K, Ebinuma H, Saito H, Kanai T. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS One. 2017;12:e0179096. [PMID: 28617830 DOI: 10.1371/journal.pone.0179096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
14 Wei K, Jiang BC, Guan JH, Zhang DN, Zhang MX, Wu JL, Zhu GZ. Decreased CD4+CD25+CD127dim/- Regulatory T Cells and T Helper 17 Cell Responsiveness to Toll-Like Receptor 2 in Chronic Hepatitis C Patients with Daclatasvir Plus Asunaprevir Therapy. Viral Immunol 2018;31:559-67. [PMID: 30067145 DOI: 10.1089/vim.2018.0055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Chenna Narendra S, Chalise JP, Biggs S, Kalinke U, Magnusson M. Regulatory T-Cells Mediate IFN-α-Induced Resistance against Antigen-Induced Arthritis. Front Immunol 2018;9:285. [PMID: 29515584 DOI: 10.3389/fimmu.2018.00285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Parisi SG, Andreis S, Basso M, Cavinato S, Scaggiante R, Franzetti M, Andreoni M, Palù G, Cattelan AM. Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals. Med Microbiol Immunol 2017;206:419-28. [PMID: 28864951 DOI: 10.1007/s00430-017-0518-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
17 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci 2020;21:E5644. [PMID: 32781731 DOI: 10.3390/ijms21165644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Ghosh A, Mondal RK, Romani S, Bagchi S, Cairo C, Pauza CD, Kottilil S, Poonia B. Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure. J Viral Hepat 2019;26:1105-16. [PMID: 31074195 DOI: 10.1111/jvh.13121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
20 Pascut D, Cavalletto L, Pratama MY, Bresolin S, Trentin L, Basso G, Bedogni G, Tiribelli C, Chemello L. Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers (Basel) 2019;11:E1773. [PMID: 31717959 DOI: 10.3390/cancers11111773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
21 Ravens S, Hengst J, Schlapphoff V, Deterding K, Dhingra A, Schultze-Florey C, Koenecke C, Cornberg M, Wedemeyer H, Prinz I. Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. Front Immunol 2018;9:510. [PMID: 29616028 DOI: 10.3389/fimmu.2018.00510] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
22 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
23 Tumino N, Casetti R, Fabbri G, Cimini E, Romanelli A, Turchi F, Forini O, Bordoni V, Antinori A, Ammassari A, Sacchi A, Agrati C. In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. Journal of Hepatology 2017;67:422-4. [DOI: 10.1016/j.jhep.2017.03.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
24 Osuch S, Metzner KJ, Caraballo Cortés K. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020;12:E799. [PMID: 32722372 DOI: 10.3390/v12080799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Zientarska A, Kaczmarek M, Mozer-Lisewska I, Kowala-Piaskowska A, Witkowska A, Żeromski J. Treg cells in the course of chronic hepatitis C virus infection partially normalize in longitudinal observation after successful DAA treatment regardless of hepatic fibrosis stage. Clin Exp Hepatol 2021;7:196-204. [PMID: 34295988 DOI: 10.5114/ceh.2021.107122] [Reference Citation Analysis]
26 Polyak SJ, Crispe IN, Baumert TF. Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. Pathogens 2021;10:44. [PMID: 33430338 DOI: 10.3390/pathogens10010044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Reference Citation Analysis]
28 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
29 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Lampejo T, Agarwal K, Carey I. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. Dig Liver Dis 2018;50:113-23. [PMID: 29233687 DOI: 10.1016/j.dld.2017.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Stuart JD, Salinas E, Grakoui A. Immune system control of hepatitis C virus infection. Curr Opin Virol. 2021;46:36-44. [PMID: 33137689 DOI: 10.1016/j.coviro.2020.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ghosh A, Romani S, Kottilil S, Poonia B. Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal. Int J Mol Sci. 2020;21. [PMID: 33050486 DOI: 10.3390/ijms21207473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Churov AV, Mamashov KY, Novitskaia AV. Homeostasis and the functional roles of CD4+ Treg cells in aging. Immunol Lett 2020;226:83-9. [PMID: 32717201 DOI: 10.1016/j.imlet.2020.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Mazouz S, Boisvert M, Shoukry NH, Lamarre D. Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. CanLivJ 2018;1:78-105. [DOI: 10.3138/canlivj.1.2.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
36 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Han JW, Sung PS, Kim KH, Hong SH, Shin EC, Jun Song M, Park SH. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection. J Infect Dis 2019;220:1290-301. [PMID: 31152667 DOI: 10.1093/infdis/jiz291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
38 Montero N, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev 2018;5:CD011403. [PMID: 29734473 DOI: 10.1002/14651858.CD011403.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
39 Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer 2019;8:41-65. [PMID: 30815394 DOI: 10.1159/000490360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
40 Dold L, Hausen A, Langhans B, Strassburg CP, Spengler U. Transient flare of psoriasis under direct‐acting antiviral therapy of chronic hepatitis C: A case report. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5647] [Reference Citation Analysis]
41 Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert Opinion on Pharmacotherapy 2017;19:49-64. [DOI: 10.1080/14656566.2017.1419185] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
42 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
43 Langhans B, Spengler U. Reply to: "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals". J Hepatol 2017;67:424-5. [PMID: 28404219 DOI: 10.1016/j.jhep.2017.03.034] [Reference Citation Analysis]
44 Strunz B, Hengst J, Deterding K, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK. Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nat Commun 2018;9:2275. [PMID: 29891939 DOI: 10.1038/s41467-018-04685-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
45 Gaglio PJ. Extrahepatic and Intrahepatic Malignancies in Patients With HCV Who Achieve an SVR With Directly Acting Antiviral Agents: Should We be Concerned that DAA Therapy Contributed to this Phenomenon? J Clin Gastroenterol 2017;51:657-8. [PMID: 28796002 DOI: 10.1097/MCG.0000000000000892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
46 Binder B, Thimme R. CD4+ T cell responses in human viral infection: lessons from hepatitis C. J Clin Invest 2020;130:595-7. [PMID: 31904589 DOI: 10.1172/JCI133222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
47 Wu SF, Tseng CW, Ho YC, Chen YC, Ko PH, He YT, Tseng KC. Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients. Dig Dis Sci 2020;65:1385-95. [PMID: 31559553 DOI: 10.1007/s10620-019-05850-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Han JW, Sung PS, Hong SH, Lee H, Koh JY, Lee H, White S, Maslow JN, Weiner DB, Park SH, Jeong M, Heo J, Ahn SH, Shin EC. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. J Hepatol 2020;73:72-83. [PMID: 32088322 DOI: 10.1016/j.jhep.2020.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
49 Telatin V, Nicoli F, Frasson C, Menegotto N, Barbaro F, Castelli E, Erne E, Palù G, Caputo A. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment. Front Cell Infect Microbiol 2019;9:190. [PMID: 31259160 DOI: 10.3389/fcimb.2019.00190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
50 Sakai H, Miwa T, Ikoma Y, Hanai T, Nakamura N, Imai K, Kitagawa J, Shirakami Y, Kanemura N, Suetsugu A, Takai K, Shiraki M, Shimizu M. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review. Mol Clin Oncol 2020;13:1. [PMID: 32754315 DOI: 10.3892/mco.2020.2071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Garcia-Broncano P, Medrano LM, Berenguer J, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Guardiola JM, Crespo M, Quereda C, Sanz J, García-Gómez AB, Jimenez JL, Resino S; GESIDA 3603b Study Group. Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status. Cells 2018;7:E196. [PMID: 30400258 DOI: 10.3390/cells7110196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
52 Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol 2020;11:571166. [PMID: 33133084 DOI: 10.3389/fimmu.2020.571166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Villani R, Romano AD, Sangineto M, Serviddio G. Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease. Intern Emerg Med 2021;16:1239-45. [PMID: 33471254 DOI: 10.1007/s11739-020-02628-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Han JW, Yoon SK. Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma. Int J Mol Sci 2020;22:E232. [PMID: 33379384 DOI: 10.3390/ijms22010232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]